Exosomal miR-208b related with oxaliplatin resistance promotes Treg expansion in colorectal cancer

[1]  Joon-Oh Park,et al.  Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial. , 2019, Journal of Clinical Oncology.

[2]  Y. Ba,et al.  miR-135b Delivered by Gastric Tumor Exosomes Inhibits FOXO1 Expression in Endothelial Cells and Promotes Angiogenesis. , 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

[3]  G. Xiong,et al.  Delivery of Anti-miRNA for Triple-Negative Breast Cancer Therapy Using RNA Nanoparticles Targeting Stem Cell Marker CD133. , 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

[4]  V. Apostolopoulos,et al.  Oxaliplatin Treatment Alters Systemic Immune Responses , 2019, BioMed research international.

[5]  Yi Fang,et al.  Delayed Remote Ischemic Preconditioning ConfersRenoprotection against Septic Acute Kidney Injury via Exosomal miR-21 , 2019, Theranostics.

[6]  W. Leonard,et al.  Biology and regulation of IL-2: from molecular mechanisms to human therapy , 2018, Nature Reviews Immunology.

[7]  Chen Huang,et al.  Hypoxic Tumor-Derived Exosomal miR-301a Mediates M2 Macrophage Polarization via PTEN/PI3Kγ to Promote Pancreatic Cancer Metastasis. , 2018, Cancer research.

[8]  Hakho Lee,et al.  New Technologies for Analysis of Extracellular Vesicles. , 2018, Chemical reviews.

[9]  A. Jemal,et al.  Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.

[10]  Y. Ba,et al.  Exosome-delivered EGFR regulates liver microenvironment to promote gastric cancer liver metastasis , 2017, Nature Communications.

[11]  Jianwen Liu,et al.  Inhibition of polypyrimidine tract-binding protein 3 induces apoptosis and cell cycle arrest, and enhances the cytotoxicity of 5- fluorouracil in gastric cancer cells , 2017, British Journal of Cancer.

[12]  Zhen Wang,et al.  Exosomes in tumor microenvironment: novel transporters and biomarkers , 2016, Journal of Translational Medicine.

[13]  Y. Toiyama,et al.  Circulating microRNA-1290 as a novel diagnostic and prognostic biomarker in human colorectal cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  K. Leong,et al.  Inducing enhanced immunogenic cell death with nanocarrier-based drug delivery systems for pancreatic cancer therapy. , 2016, Biomaterials.

[15]  Yuchen Liu,et al.  Cell-derived microvesicles mediate the delivery of miR-29a/c to suppress angiogenesis in gastric carcinoma. , 2016, Cancer letters.

[16]  Angela L. Riffo-Campos,et al.  Emerging Role of miRNAs in the Drug Resistance of Gastric Cancer , 2016, International journal of molecular sciences.

[17]  Y. Toiyama,et al.  Circulating microRNA-203 predicts prognosis and metastasis in human colorectal cancer , 2015, Gut.

[18]  X. Chen,et al.  Tumor-secreted miR-214 induces regulatory T cells: a major link between immune evasion and tumor growth , 2014, Cell Research.

[19]  P. Miossec,et al.  Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. , 2014, Autoimmunity reviews.

[20]  Y. Toiyama,et al.  Serum miR-200c Is a Novel Prognostic and Metastasis-Predictive Biomarker in Patients With Colorectal Cancer , 2014, Annals of surgery.

[21]  X. Chen,et al.  A Combination of Let-7d, Let-7g and Let-7i Serves as a Stable Reference for Normalization of Serum microRNAs , 2013, PloS one.

[22]  B. Bao,et al.  Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review , 2013, Cancer and Metastasis Reviews.

[23]  Shinobu Ueda,et al.  Systemically Injected Exosomes Targeted to EGFR Deliver Antitumor MicroRNA to Breast Cancer Cells. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[24]  G. Liszkay,et al.  Immune cell profile of sentinel lymph nodes in patients with malignant melanoma – FOXP3+ cell density in cases with positive sentinel node status is associated with unfavorable clinical outcome , 2013, Journal of Translational Medicine.

[25]  P. Hoff,et al.  Oxaliplatin-related thrombocytopenia. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  G. Montrucchio,et al.  Potential plasticity of T regulatory cells in pancreatic carcinoma in relation to disease progression and outcome. , 2012, Experimental and therapeutic medicine.

[27]  M. Rugge,et al.  PDCD4 nuclear loss inversely correlates with miR-21 levels in colon carcinogenesis , 2011, Virchows Archiv.

[28]  Caifu Chen,et al.  Quantitation of microRNAs by real-time RT-qPCR. , 2011, Methods in molecular biology.

[29]  Lin Zhao,et al.  5-Fluorouracil and oxaliplatin modify the expression profiles of microRNAs in human colon cancer cells in vitro. , 2009, Oncology reports.

[30]  H. Allgayer.  Pdcd4, a colon cancer prognostic that is regulated by a microRNA. , 2007, Critical reviews in oncology/hematology.

[31]  Xi Chen,et al.  Role of microRNA in anticancer drug resistance , 2010, International journal of cancer.

[32]  J. Rak,et al.  Microvesicles: Messengers and mediators of tumor progression , 2009, Cell cycle.

[33]  C. Qin,et al.  Programmed cell death 4 (PDCD4) suppresses metastastic potential of human hepatocellular carcinoma cells , 2009, Journal of experimental & clinical cancer research : CR.

[34]  T. Nomura,et al.  Regulatory T Cells and Immune Tolerance , 2008, Cell.

[35]  Zijie Sun,et al.  Downregulation of tumor suppressor Pdcd4 promotes invasion and activates both β-catenin/Tcf and AP-1-dependent transcription in colon carcinoma cells , 2008, Oncogene.

[36]  A. Godkin,et al.  Regulatory T cells and tumour immunity – observations in mice and men , 2007, Immunology.

[37]  L. Kèlland,et al.  The resurgence of platinum-based cancer chemotherapy , 2007, Nature Reviews Cancer.

[38]  M. Joshi,et al.  Tumor infiltrating Foxp3+ regulatory T‐cells are associated with recurrence in pathologic stage I NSCLC patients , 2006, Cancer.

[39]  Stephen B Fox,et al.  Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  N. Colburn,et al.  Tumorigenesis Suppressor Pdcd4 Down-Regulates Mitogen-Activated Protein Kinase Kinase Kinase Kinase 1 Expression To Suppress Colon Carcinoma Cell Invasion , 2006, Molecular and Cellular Biology.

[41]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[42]  Li Li,et al.  Conversion of Peripheral CD4+CD25− Naive T Cells to CD4+CD25+ Regulatory T Cells by TGF-β Induction of Transcription Factor Foxp3 , 2003, The Journal of experimental medicine.

[43]  Iver Petersen,et al.  Loss of PDCD4 expression in human lung cancer correlates with tumour progression and prognosis , 2003, The Journal of pathology.

[44]  Laurence Zitvogel,et al.  Exosomes: composition, biogenesis and function , 2002, Nature Reviews Immunology.

[45]  W. Park,et al.  Up-regulation of PDCD4 in senescent human diploid fibroblasts. , 2002, Biochemical and biophysical research communications.

[46]  B. Skogseid,et al.  Differentially expressed cDNAs in PLCbeta3-induced tumor suppression in a human endocrine pancreatic tumor cell line: activation of the human mismatch repair protein 3 gene. , 2001, Biochemical and biophysical research communications.

[47]  L. Azzoni,et al.  Differential transcriptional regulation of CD161 and a novel gene, 197/15a, by IL-2, IL-15, and IL-12 in NK and T cells. , 1998, Journal of immunology.